MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 2, 2013, Pages

  Dale Brown, R ^a   Kelly Ambler, S ^b   Li, Min ^a   Sullivan, Timothy M ^b   Henry, Lauren N ^a   Crossno, Joseph T ^b   Long, Carlin S ^b   Garrington, Timothy P ^a   Stenmark, Kurt R ^a  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac remodeling; ERK5; Hypoxia; Inflammation; Mitogen activated protein kinase kinase kinase 2; Myocytes; Pulmonary hypertension

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART MUSCLE CELL; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; THICKNESS;

EID: 84872393859     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00158.2012     Document Type: Article

References (65)

1. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 87: F15-F18, 2002.
2. Ambler SK, Hodges YK, Jones GM, Long CS, Horwitz LD. Prolonged administration of a dithiol antioxidant protects against ventricular remodeling due to ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 295: H1303-H1310, 2008.
3. Anversa P, Olivetti G. Cellular basis of physiological and pathological myocardial growth. In: The Heart, edited by Page E, Fozzard HA, Solaro RJ. New York: Oxford Univ. Press, 2002, p. 75-144.
4. Armstrong WF, Ryan T. Feigenbaum's Echocardiography (7th ed.). Baltimore, MD: Lippincott, Williams & Wilkins, 2010.
5. Balakumar P, Singh AP, Ganti SS, Krishan P, Ramasamy S, Singh M. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy? Basic Clin Pharmacol Toxicol 102: 5-9, 2008.
6. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120: 1951-1960, 2009.
7. Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D, Stenmark KR. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 297: L238-L250, 2009.
8. Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 373: 391-400, 2006.
9. Chen LM, Kuo WW, Yang JJ, Wang SG, Yeh YL, Tsai FJ, Ho YJ, Chang MH, Huang CY, Lee SD. Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia in rats. Exp Physiol 92: 409-416, 2007.
10. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 16: 13-18, 2005.
11. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292: L885-L897, 2007.
12. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, Lingen MW, Rosner MR. A novel interplay between Epac/Rap1 and MEK5/ERK5 regulates thrombospondin to control angiogenesis. Blood 114: 4592-4600, 2009.
13. Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, Rodman DM. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 103: 291-299, 1999.
14. Fouron JC, Le Guennec JC, Villemant D, Perreault G, Davignon A. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. Pediatrics 65: 529-535, 1980.
15. Frid MG, Li M, Gnanasekharan M, Burke DL, Fragoso M, Strassheim D, Sylman JL, Stenmark KR. Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall. Am J Physiol Lung Cell Mol Physiol 297: L1059-L1072, 2009.
16. Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. Am J Cardiol 96: 10L-18L, 2005.
17. Garrington TP, Ishizuka T, Papst PJ, Chayama K, Webb S, Yujiri T, Sun W, Sather S, Russell DM, Gibson SB, Keller G, Gelfand EW, Johnson GL. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. EMBO J 19: 5387-5395, 2000.
18. Garrington TP, Johnson GL. Organization and regulation of mitogenactivated protein kinase signaling pathways. Curr Opin Cell Biol 11: 211-218, 1999.
19. Ha T, Hua F, Li Y, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, Browder IW, Kao RL, Li C. Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 290: H985-H994, 2006.
20. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 13: 863-875, 2001.
21. Hammaker DR, Boyle DL, Chabaud-Riou M, Firestein GS. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 172: 1612-1618, 2004.
22. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. Big mitogenactivated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 65: 7699-7706, 2005.
23. Hayashi M, Lee JD. Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice. J Mol Med 82: 800-808, 2004.
24. Jeong MY, Kinugawa K, Vinson C, Long CS. AFos dissociates myocyte hypertrophy and expression of the pathological gene program. Circulation 111: 1645-1651, 2005.
25. Jeong MY, Walker JS, Brown RD, Moore RL, Vinson CS, Colucci WS, Long CS. AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation. Am J Physiol Heart Circ Physiol 298: H1719-H1726, 2010.
26. Jiang B, Liao R. The paradoxical role of inflammation in cardiac repair and regeneration. J Cardiovasc Transl Res 3: 410-416, 2010.
27. Kawut SM, Al-Naamani N, Agerstrand C, Rosenzweig EB, Rowan C, Barst RJ, Bergmann S, Horn EM. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest 135: 752-759, 2009.
28. Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL, Garrington TP. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. J Cell Physiol 199: 140-148, 2004.
29. Kimura TE, Jin J, Zi M, Prehar S, Liu W, Oceandy D, Abe J, Neyses L, Weston AH, Cartwright EJ, Wang X. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 106: 961-970, 2010.
30. Kinderlerer AR, Ali F, Johns M, Lidington EA, Leung V, Boyle JJ, Hamdulay SS, Evans PC, Haskard DO, Mason JC. KLF2-dependent, shear stress-induced expression of CD59: a novel cytoprotective mechanism against complement-mediated injury in the vasculature. J Biol Chem 283: 14636-14644, 2008.
31. Kuida K, Boucher DM. Functions of MAP kinases: insights from gene-targeting studies. J Biochem 135: 653-656, 2004.
32. Lemler MS, Bies RD, Frid MG, Sastravaha A, Zisman LS, Bohlmeyer T, Gerdes AM, Reeves JT, Stenmark KR. Myocyte cytoskeletal disorganization and right heart failure in hypoxia-induced neonatal pulmonary hypertension. Am J Physiol Heart Circ Physiol 279: H1365-H1376, 2000.
33. Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, McKeon BA, Lemon DD, Horn TR, Anwar A, Barajas C, Stenmark KR. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol 187: 2711-2722, 2011.
34. Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24: 883-896, 2003.
35. Littler CM, Morris KG Jr, Fagan KA, McMurtry IF, Messing RO, Dempsey EC. Protein kinase C-ε-null mice have decreased hypoxic pulmonary vasoconstriction. Am J Physiol Heart Circ Physiol 284: H1321-H1331, 2003.
36. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of _-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100: 2315-2324, 1997.
37. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 48, Suppl 3: iii25-iii31, 2009.
38. Mitchell MD, Laird RE, Brown RD, Long CS. IL-1β stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am J Physiol Heart Circ Physiol 292: H1139-H1147, 2007.
39. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54: S20-S31, 2009.
40. Mudd JO, Kass DA. Reversing chronic remodeling in heart failure. Expert Rev Cardiovasc Ther 5: 585-598, 2007.
41. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 20: 2757-2767, 2001.
42. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7: 782-786, 2006.
43. Purevdorj E, Zscheppang K, Hoymann HG, Braun A, von MD, Brinkhaus MJ, Schmiedl A, Dammann CE. ErbB4 deletion leads to changes in lung function and structure similar to bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 294: L516-L522, 2008.
44. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol 2: 369-399, 2007.
45. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 4: 211-221, 2006.
46. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 12: 331-343, 2007.
47. Ravingerova T, Barancik M, Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247: 127-138, 2003.
48. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99: 9248-9253, 2002.
49. Schaefer BC, Ware MF, Marrack P, Fanger GR, Kappler JW, Johnson GL, Monks CR. Live cell fluorescence imaging of T cell MEKK2: redistribution and activation in response to antigen stimulation of the T cell receptor. Immunity 11: 411-421, 1999.
50. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94: 1101-1108, 2004.
51. Schweppe RE, Cheung TH, Ahn NG. Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. J Biol Chem 281: 20993-21003, 2006.
52. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63: 373-380, 2004.
53. Sohn SJ, Sarvis BK, Cado D, Winoto A. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277: 43344-43351, 2002.
54. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927, 2010.
55. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691, 2006.
56. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-L1032, 2009.
57. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 76: 725-746, 1998.
58. Walker LA, Buttrick PM. The right ventricle: biologic insights and response to disease. Curr Cardiol Rev 5: 22-28, 2009.
59. Walker LA, Walker JS, Glazier A, Brown DR, Stenmark KR, Buttrick PM. Biochemical and myofilament responses of the right ventricle to severe pulmonary hypertension. Am J Physiol Heart Circ Physiol 301: H832-H840, 2011.
60. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 116: 1413-1423, 2007.
61. Wang Y, Su B, Xia Z. Brain-derived neurotrophic factor activates ERK5 in cortical neurons via a Rap1-MEKK2 signaling cascade. J Biol Chem 281: 35965-35974, 2006.
62. Wei X, Sun W, Fan R, Hahn J, Joetham A, Li G, Webb S, Garrington T, Dakhama A, Lucas J, Johnson GL, Gelfand EW. MEF2C regulates c-Jun but not TNF-_ gene expression in stimulated mast cells. Eur J Immunol 33: 2903-2909, 2003.
63. Xie L, Jing L, Yu Y, Nakamura K, Parker CE, Johnson GL, Chen X. In vivo profiling endogenous interactions with knock-out in mammalian cells. Anal Chem 81: 1411-1417, 2009.
64. Yamashita M, Ying SX, Zhang GM, Li C, Cheng SY, Deng CX, Zhang YE. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121: 101-113, 2005.
65. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 9: 236-241, 2007.